Andrew Plump, M.D., Ph.D., is the president of Research & Development at Takeda Pharmaceutical Company Limited and serves as a member of the company’s board of directors. His career spans nearly 30 years in the pharmaceutical industry and academia and his experience encompasses early research through regulatory approval and patient access.
Dr. Plump oversees Takeda’s global R&D organization of more than 5,000 employees. Early in his tenure he orchestrated a multi-year strategic and cultural transformation that has resulted in a renewed focus on innovation, streamlined global footprint, prioritized therapeutic areas of focus, a rich network of partnerships and a modality-diverse portfolio of newly approved and promising late-stage development experimental therapies. He also championed efforts to build an exciting and sustainable early development and research pipeline, founded on strong translational science as well as platform capabilities in cell therapy, gene therapy and data sciences. Over the last several years, Dr. Plump has substantially increased the company’s investment in research and partnerships and the launch and growth of medicines that provide meaningful benefit to society.
Dr. Plump has been recognized for his contributions to the healthcare industry, education and the arts. He serves on several not-for-profit boards including the board of directors of the PhRMA Foundation, the Sarnoff Cardiovascular Research Foundation and the Biomedical Science Careers Program. He also serves in advisory board positions at BioCentury and the Boston Symphony Orchestra.
Prior to Takeda, Dr. Plump served as head of Research & Translational Medicine, deputy to the president of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as worldwide cardiovascular (CV) research head at Merck.
Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in internal medicine and a fellowship in medical genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an adjunct clinical instructor in the department of medical genetics.
